Skip to main
INVA
INVA logo

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 50%
Sell 17%
Strong Sell 0%

Bulls say

Innoviva Inc. demonstrates a strong financial position with $178.4 million in cash and cash equivalents, alongside $76.0 million in royalty and net product sales receivables, which provide significant financial flexibility. The company's profitability is bolstered by its diverse portfolio, particularly its collaboration with GSK on respiratory products, which is critical for near-term growth. Overall, Innoviva's solid cash reserves and revenue-generating assets position it favorably for future advancements and commercial success in the healthcare sector.

Bears say

Innoviva Inc. experienced a significant non-cash charge of $90.7 million in 2Q24 due to a decline in the share price of Armata Pharmaceuticals, indicating potential volatility in its investment portfolio. Furthermore, the royalties expected from GSK agreements are projected to be lower than anticipated, posing a risk to Innoviva's revenue stream and overall financial stability. This combination of investment losses and reduced royalty income raises concerns regarding Innoviva's future performance and stock valuation.

Innoviva (INVA) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Hold based on their latest research and market trends.

According to 6 analysts, Innoviva (INVA) has a Hold consensus rating as of Jun 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.